Among the newest pharmacological advancements approved for treating age-related blurry near vision (presbyopia) is VIZZ (aceclidine ophthalmic solution 1.44%), developed by LENZ Therapeutics. As a pupil-selective miotic eye drop designed to improve near vision for up to 10 hours without overly impacting distance focus, it provides adults with an innovative non-invasive alternative to traditional reading glasses and surgical procedures.